Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Buys $13,020.00 in Stock

Share on StockTwits

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Matthew T. Plavan acquired 2,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was purchased at an average cost of $6.51 per share, with a total value of $13,020.00. Following the completion of the acquisition, the chief executive officer now owns 9,000 shares of the company’s stock, valued at $58,590. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NASDAQ:RKDA opened at $5.68 on Friday. The firm has a market capitalization of $46.26 million, a PE ratio of -1.06 and a beta of -2.94. The stock has a 50 day moving average of $5.35 and a 200-day moving average of $5.37. Arcadia Biosciences Inc has a 52 week low of $1.82 and a 52 week high of $10.40. The company has a current ratio of 5.29, a quick ratio of 5.09 and a debt-to-equity ratio of 0.19.

Several analysts recently weighed in on RKDA shares. ValuEngine lowered Arcadia Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, August 15th. National Securities boosted their price objective on Arcadia Biosciences from $12.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Arcadia Biosciences in a report on Monday, August 12th.

Several large investors have recently bought and sold shares of the company. CVI Holdings LLC bought a new position in shares of Arcadia Biosciences during the second quarter valued at approximately $414,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Arcadia Biosciences during the second quarter valued at approximately $34,000. Citadel Advisors LLC bought a new position in shares of Arcadia Biosciences during the second quarter valued at approximately $32,000. Morgan Stanley grew its holdings in shares of Arcadia Biosciences by 162,800.0% during the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock valued at $250,000 after purchasing an additional 81,400 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Arcadia Biosciences by 47.1% during the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock valued at $359,000 after purchasing an additional 37,472 shares during the last quarter. 7.67% of the stock is owned by institutional investors.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Featured Article: LIBOR

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.